Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin

BACKGROUND: The incidence of malignant pleural mesothelioma (MPM) is associated with exposure to asbestos, and projections suggest that the yearly number of deaths in Western Europe due to MPM will increase until 2020. Despite progress in chemo- and in multimodality therapy, MPM remains a disease wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Belyanskaya, Larisa L, Marti, Thomas M, Hopkins-Donaldson, Sally, Kurtz, Stefanie, Felley-Bosco, Emanuela, Stahel, Rolf A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2134932/
https://www.ncbi.nlm.nih.gov/pubmed/17953743
http://dx.doi.org/10.1186/1476-4598-6-66

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2134932/
https://www.ncbi.nlm.nih.gov/pubmed/17953743
http://dx.doi.org/10.1186/1476-4598-6-66

Ejemplares similares